DNA microarray-based studies report differentially methylated positions (DMPs) in blood between late-onset dementia due to Alzheimer’s disease (AD) and cognitively unimpaired individuals, but interrogate < 4% of the genome.
We used whole genome methylation sequencing (WGMS) to quantify DNA methylation levels at 25,409,826 CpG loci in 281 blood samples from 108 AD and 173 cognitively unimpaired individuals.
WGMS identified 28,038 DMPs throughout the human methylome, including 2707 differentially methylated genes (e.g., SORCS3, GABA, and PICALM) encoding proteins in biological pathways relevant to AD such as synaptic membrane, cation channel complex, and glutamatergic synapse. One hundred seventy-three differentially methylated blood-specific enhancers interact with the promoters of 95 genes that are differentially expressed in blood from persons with and without AD.
WGMS identifies differentially methylated CpGs in known and newly detected genes and enhancers in blood from persons with and without AD.
Whole genome DNA methylation levels were quantified in blood from persons with and without Alzheimer’s disease (AD).
Twenty-eight thousand thirty-eight differentially methylated positions (DMPs) were identified.
Two thousand seven hundred seven genes comprise DMPs.
Forty-eight of 75 independent genetic risk loci for AD have DMPs.
One thousand five hundred sixty-eight blood-specific enhancers comprise DMPs, 173 of which interact with the promoters of 95 genes that are differentially expressed in blood from persons with and without AD.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Coleman Breen,
Ligia A. Papale,
Lindsay R. Clark,
Phillip E. Bergmann,
Sterling C. Johnson,
Reid S. Alisch,
Kirk J. Hogan | October 20, 2023